Integrating CDK4/6 inhibitors in the treatment of patients with early breast cancer

Por Sibylle Loibl, Jenny Furlanetto
Publicado em 2022-03-01

Understanding the barriers to, and facilitators of, ovarian toxicity assessment in breast cancer clinical trials

Por Wanyuan Cui, Kelly-Anne Phillips, Prudence A. Francis, Richard A. Anderson, Ann H. Partridge, Sherene Loi, Sibylle Loibl, Louise Keogh
Publicado em 2022-08-01

Radiological Patterns of Brain Metastases in Breast Cancer Patients: A Subproject of the German Brain Metastases in Breast Cancer (BMBC) Registry

Por Elena Laakmann, Isabell Witzel, Verena Scriba, Ulrich Grzyska, Christine zu Eulenburg, Nicole Burchardi, Tobias Hesse, Florian Würschmidt, Tanja Fehm, Volker Möbus, Gunter von Minckwitz, Sibylle Loibl, Tjoung-Won Park-Simon, Volkmar Mueller
Publicado em 2016-09-01

Clinical Relevance of Collagen Protein Degradation Markers C3M and C4M in the Serum of Breast Cancer Patients Treated with Neoadjuvant Therapy in the GeparQuinto Trial

Por Malgorzata Banys-Paluchowski, Sibylle Loibl, Isabell Witzel, Christoph Mundhenke, Bianca Lederer, Christine Solbach, Thomas Karn, Frederik Marmé, Valentina Nekljudova, Christian Schem, Elmar Stickeler, Nicholas Willumsen, Morten A. Karsdal, Michael Untch, Volkmar Müller
Publicado em 2019-08-01